Expanding the Product Portfolio Through New Product Launches

「In the cardiovascular field, we developed PRISMbros, a PCI guidewire for CTOs (chronic total occlusions).」

「Sales in the cardiovascular field increased in all regions, led by PCI guidewires.」

「We developed the peripheral vascular treatment guidewires CROSSLEAD Penetration and CROSSLEAD Tracker. Sales of both products have begun in Japan and the United States. We also developed the neurovascular treatment guidewire CHIKAI Nexus 014, with sales beginning in Japan.」

「In the peripheral vascular field, we developed the peripheral vascular treatment guidewires CROSSLEAD Penetration and CROSSLEAD Tracker.」

「In the non-cardiovascular field, net sales increased in all regions, driven by the effects of new products such as CROSSLEAD in the U.S. peripheral vascular product market and growth in abdominal products in the U.S. and Chinese markets.」

「In the non-cardiovascular field, net sales increased due to growth across all fields in the Chinese market and higher sales in the U.S. market driven by the new-product effects of CROSSLEAD and CROSSWALK peripheral vascular products.」

「In the non-cardiovascular field, sales increased due to higher sales of peripheral vascular products in the U.S. market, driven by the new-product effects of CROSSLEAD and CROSSWALK, strong performance by abdominal vascular products in the Chinese market, and steady growth in OEM transactions, including an increase in new transactions, mainly in the United States.」

「As a measure toward achieving this, during the consolidated fiscal year, we began selling the new “CROSSLEAD” peripheral vascular guidewire in the U.S. market.」

「As measures toward achieving this, during the three months ended the first quarter, we entered into ① a basic agreement for the exclusive distribution in Japan of Penumbra Inc.’s (U.S.) thrombus aspiration devices for peripheral vessels, ② an exclusive distribution agreement in China for DK MEDTECH (Suzhou) Co., Ltd.’s “DK Score coronary scoring balloon dilatation catheter,” and ③ issued the Group’s first “Integrated Report 2022.”」

「In the guidewire product field, GAIA Next 4th, a guidewire for chronic total occlusions, was developed as the latest addition to the GAIA Next series. By further advancing the technologies developed through the existing GAIA Next products, it maintains the series' characteristics while improving penetration through hard stenotic lesions. In the new nonvascular field, we developed Fealder25, an ERCP guidewire. We also developed Tornus ES as a gastrointestinal dilator. Unlike conventional electrosurgical dilators, this device can easily penetrate to the target site through rotation from the proximal end. It was developed by combining core technology with product technologies cultivated through our vascular penetration catheters to meet clinical needs.」

「We newly developed GAIA NEXT 4, part of the GAIA Next series for chronic total occlusion lesions, with improved penetration power. We also developed KAMUI XS, a small-diameter balloon catheter with improved crossability through stenotic lesions, particularly in the treatment of chronic total occlusions. In addition, we developed CHIKAI X 014 SOFT, a guidewire for neurovascular intervention targeting the European and U.S. markets based on needs in those markets.」

「As measures to achieve this, during the current consolidated fiscal year we began selling the new nickel-titanium hybrid PTCA guidewire MINAMO (ミナモ) and the neurovascular balloon guide catheter Branchor (ブランカー).」

「As measures to achieve this, during the nine months ended 31 December of the current fiscal year we began selling the new nickel-titanium hybrid PTCA guidewire MINAMO (ミナモ) and the neurovascular balloon guide catheter Branchor (ブランカー).」

「As a measure toward achieving this, during the six months ended the second quarter, we began selling the new nickel-titanium hybrid PTCA guidewire “MINAMO” and the balloon-tipped guiding catheter for cerebrovascular applications “Branchor.”」

「As a measure toward achieving this, during the three months ended the first quarter, we began limited sales of the new nickel-titanium hybrid PTCA guidewire “MINAMO” and the balloon-tipped guiding catheter for cerebral applications “Branchor.”」

「In the guidewire product field, where we have our strongest capabilities, we developed MINAMO, a PTCA guidewire combining nickel titanium and stainless steel. To meet the needs of U.S. physicians, we also developed the PTCA guidewire Gladius MG/MONGO, whose small curved tip can pass through stenotic lesions. In the catheter product field, we developed Corsair Pro XS, a penetration catheter for the retrograde approach in cardiovascular procedures, with improved crossability in small vessels with sharp bends. We also developed Branchor, a balloon guide catheter used to treat cerebral infarction.」

「In the guidewire product field, where we have our strongest capabilities, we developed CHIKAI X 010, a neurovascular guidewire offering excellent distal reach while maintaining maneuverability in distal vessels. We also developed CHIKAI Black 18 soft Tip, an addition to the CHIKAI Black 18 line of guidewires sold for cerebral artery treatment, which can also be used to treat cerebral infarction, or cerebral artery occlusion caused by a thrombus.」

「As measures toward achieving this, during the nine months ended the third quarter, we began operating the newly established medical factory at TOYOFLEX CEBU CORPORATION (the Cebu manufacturing plant in the Philippines), acquired all shares of 日本ケミカルコート株式会社, which has resin coating technology (making it a non-consolidated subsidiary after the acquisition), began selling the “Silverway” guidewire for diagnostic procedures, and resolved to begin direct sales from July 2018 of our core PTCA guidewires in the U.S. market, further reinforcing the Group’s strengths.」

「Sales of PTCA guidewires and the penetration catheter SASUKE (サスケ) continued to grow. Sales of the new PTCA balloon catheter NC kamui (エヌシーカムイ) also increased as it gained market share, resulting in strong performance.」

「Sales of PTCA guidewires and the penetration catheter SASUKE (サスケ) continued to grow. Sales of the new PTCA balloon catheter NC-kamui (エヌシーカムイ) also increased as it gained market share, resulting in strong performance.」

「In the cardiovascular field, in addition to strengthening our range of therapeutic products, we have also been strengthening our diagnostic product capabilities. We newly developed the diagnostic guidewire Silverway (シルバーウェイ), which offers torque response and other characteristics not available in our existing products. In the non-cardiovascular field, we developed Meister S14 (マイスター エスイチヨン) as an abdominal guidewire for liver cancer treatment, with the ability to reach highly tortuous peripheral blood vessels.」

「As measures toward achieving this, during the nine months ended the third quarter, we began selling the “NC-KAMUI” high-pressure PTCA balloon catheter in the cardiovascular field and the “M-ThroughTM” endoscopic guidewire for the bile duct, pancreatic duct and gastrointestinal fields, a new business area, in Japan. In overseas markets, we advanced the rollout of products already sold and highly regarded in Japan. In Europe, we began selling the “Caravel” and “Corsair Pro” crossing catheters and the “Hyperion” PTCA guiding catheter in the cardiovascular field, and in the United States, we began selling products including the “Corsair Pro” crossing catheter in the cardiovascular field.」

「As a measure toward achieving this, during the six months ended the second quarter, we began selling the “M-ThroughTM” endoscopic guidewire for the bile duct, pancreatic duct and gastrointestinal fields in Japan, which are new areas for our business. In overseas markets, we began selling the “Caravel” crossing catheter and “Hyperion” PTCA guiding catheter in Europe, both of which are already sold and highly regarded in Japan, and changed our sales strategy in China to a model involving sales through multiple distributors for cardiovascular products.」

「As a measure toward achieving this, during the three months ended the first quarter, we began selling the “M-ThroughTM” endoscopic guidewire for the bile duct, pancreatic duct and gastrointestinal fields in Japan, which are new areas for our business. In overseas markets, we also began limited sales in Europe of the “Caravel” crossing catheter and “Hyperion” PTCA guiding catheter in the cardiovascular field, both of which are already sold and highly regarded in Japan, as well as peripheral guidewires for the non-cardiovascular peripheral vascular field.」

「As measures to achieve this, during the current consolidated fiscal year we began selling several new products in Japan, including the general-use PTCA guidewire SION-BLUE-ES (シオンブルーイーエス), the CTO (chronic total occlusion) guidewire SUOH03 (スオウゼロスリー), and the multifunction-type penetration catheter SASUKE (サスケ).」